Oncology Institute (TOI) to Post Quarterly Earnings on Thursday

Oncology Institute (NASDAQ:TOI) is expected to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Oncology Institute to announce earnings of ($0.07) per share and revenue of $155.28 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Oncology Institute (NASDAQ:TOI) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. The company had revenue of $147.44 million for the quarter, compared to the consensus estimate of $142.10 million. On average, analysts expect Oncology Institute to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Oncology Institute Trading Down 3.6%

NASDAQ:TOI opened at $4.77 on Thursday. The stock has a market capitalization of $471.47 million, a PE ratio of -12.89 and a beta of 0.36. Oncology Institute has a 1-year low of $2.32 and a 1-year high of $6.67. The firm has a fifty day simple moving average of $5.16 and a 200 day simple moving average of $3.89.

Wall Street Analysts Forecast Growth

TOI has been the subject of a number of analyst reports. Lake Street Capital started coverage on shares of Oncology Institute in a research report on Monday, July 6th. They issued a “buy” rating and a $10.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a report on Friday, July 17th. BTIG Research upped their price objective on Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Finally, Needham & Company LLC lifted their target price on Oncology Institute from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Oncology Institute currently has an average rating of “Moderate Buy” and an average price target of $8.50.

Insider Activity

In other news, major shareholder Jorey Chernett bought 33,500 shares of the stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $4.07 per share, for a total transaction of $136,345.00. Following the completion of the purchase, the insider owned 10,567,858 shares in the company, valued at approximately $43,011,182.06. This trade represents a 0.32% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Yale Podnos sold 23,451 shares of Oncology Institute stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $5.38, for a total value of $126,166.38. Following the sale, the insider directly owned 259,527 shares of the company’s stock, valued at approximately $1,396,255.26. The trade was a 8.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders acquired 131,500 shares of company stock worth $609,265. Insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Oncology Institute

A number of institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD increased its position in Oncology Institute by 27.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 38,002 shares of the company’s stock worth $136,000 after acquiring an additional 8,238 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of Oncology Institute during the 1st quarter worth approximately $131,000. Raymond James Financial Inc. increased its holdings in shares of Oncology Institute by 1,433.6% during the third quarter. Raymond James Financial Inc. now owns 35,748 shares of the company’s stock worth $125,000 after purchasing an additional 33,417 shares during the period. New York State Common Retirement Fund acquired a new stake in shares of Oncology Institute in the second quarter valued at approximately $92,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Oncology Institute in the second quarter valued at approximately $66,000. Institutional investors own 36.86% of the company’s stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.